anti-müllerian hormone as a predictor of chemotherapy response in hr /her2- breast cancer
Published 3 months ago • 77 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:26
rxponder: chemotherapy and endocrine therapy in hr /her2- breast cancer
-
0:55
role of chemotherapy in early hormone receptor-positive breast cancer
-
2:05
important considerations in the management of hr , her2-negative early breast cancer
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
0:57
enhertu - what it is and how it works #breastcancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
5:56
how to treat hormone receptor-positive (hr ) breast cancer: all you need to know
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
52:21
new & supporting data for optimizing therapy in her2 breast cancer | dr. irene and dr. vogel
-
14:17
anti-human epidermal growth factor receptor 2 (her2) treatments in breast cancer
-
1:25:42
hormone receptor-positive advanced breast cancer: challenges and new treatment options
-
31:21
novel therapeutics for breast cancer: her2 and triple negative disease; new pathways, targets
-
51:56
new & supporting data for optimizing therapy in her2 breast cancer | dr. kaklamani and dr. o’regan
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
32:12
education session: "escalating and de-escalation - titrating the right regimen in early stage"
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
1:19
optimizing adjuvant therapy: chemotherapy necessity in hr-positive breast cancer